Paper37339170
A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.
Keats MA and 4 others. Cancer Res, 2023. Cited by 21 papers, by iCite.
Cite this record
ConductScience Library. A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133. Papers, record 37339170. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37339170
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Histidine | Major topic |
| Proto-Oncogene Proteins p21(ras) | Major topic |
| Humans | |
| Mutation | |
| Cell Line | |
| Heterocyclic Compounds, 2-Ring | |
| Naphthalenes |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| ZIA BC011732 | Intramural NIH HHS | United States | ZIABC011732 | PubMed and NIH |
Source NIH RePORTER
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36115844 | Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma. | Nat Commun | 2022 | https://conductscience.org/library/papers/36115844 | PubMed |
| 2 | 23103856 | Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. | Cancer Discov | 2013 | https://conductscience.org/library/papers/23103856 | PubMed |
| 3 | 34889605 | Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor. | J Med Chem | 2022 | https://conductscience.org/library/papers/34889605 | PubMed |
| 4 | 34096690 | Sotorasib for Lung Cancers with KRAS p.G12C Mutation. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34096690 | PubMed |
| 5 | 35658005 | Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35658005 | PubMed |
| 6 | 31658955 | The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. | Cancer Discov | 2020 | https://conductscience.org/library/papers/31658955 | PubMed |
| 7 | 36216931 | Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. | Nat Med | 2022 | https://conductscience.org/library/papers/36216931 | PubMed |
| 8 | 34161704 | Acquired Resistance to KRASG12C Inhibition in Cancer. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34161704 | PubMed |
| 9 | 24256730 | K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. | Nature | 2013 | https://conductscience.org/library/papers/24256730 | PubMed |
| 10 | 20150892 | Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. | EMBO J | 2010 | https://conductscience.org/library/papers/20150892 | PubMed |
| 11 | 33824136 | Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. | Cancer Discov | 2021 | https://conductscience.org/library/papers/33824136 | PubMed |
| 12 | 32250617 | Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer. | J Med Chem | 2020 | https://conductscience.org/library/papers/32250617 | PubMed |
| 13 | 21993244 | RAS oncogenes: weaving a tumorigenic web. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21993244 | PubMed |
| 14 | 31666701 | The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. | Nature | 2019 | https://conductscience.org/library/papers/31666701 | PubMed |
| 15 | 36472553 | Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. | Cancer Discov | 2023 | https://conductscience.org/library/papers/36472553 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42818643 | Chemical Genetic Targeting of the LRRK2 GTPase Domain. | bioRxiv | 2026 | https://conductscience.org/library/papers/42818643 | PubMed |
| 42587080 | Brønsted-basic small molecules activate GTP hydrolysis in KRAS-Q61 mutants. | Nat Chem Biol | 2026 | https://conductscience.org/library/papers/42587080 | PubMed |
| 42365569 | Benchmarking docking and ML re-scoring screening performance for KRAS G12D in pancreatic cancer. | Mol Divers | 2026 | https://conductscience.org/library/papers/42365569 | PubMed |
| 42209458 | Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42209458 | PubMed |
| 41969551 | Emerging KRAS G12D inhibitor in the treatment of digestive system tumors: opportunities and challenges. | Transl Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/41969551 | PubMed |
| 41827015 | Systematic and precise interventions for KRAS-mutant cancers. | Exp Hematol Oncol | 2026 | https://conductscience.org/library/papers/41827015 | PubMed |
| 41801133 | Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41801133 | PubMed |
| 41129140 | Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance. | Mol Cancer Ther | 2026 | https://conductscience.org/library/papers/41129140 | PubMed |
| 40824523 | Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance. | Chin Med J (Engl) | 2025 | https://conductscience.org/library/papers/40824523 | PubMed |
| 40146324 | Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway. | Med Oncol | 2025 | https://conductscience.org/library/papers/40146324 | PubMed |
| 40140597 | A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers. | BJC Rep | 2025 | https://conductscience.org/library/papers/40140597 | PubMed |
| 39975043 | De novo design of Ras isoform selective binders. | bioRxiv | 2025 | https://conductscience.org/library/papers/39975043 | PubMed |
| 39732595 | KRAS inhibitors: resistance drivers and combinatorial strategies. | Trends Cancer | 2025 | https://conductscience.org/library/papers/39732595 | PubMed |
| 38686056 | Targeting KRAS in pancreatic cancer. | Oncol Res | 2024 | https://conductscience.org/library/papers/38686056 | PubMed |
| 38443470 | Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D. | Nat Chem Biol | 2024 | https://conductscience.org/library/papers/38443470 | PubMed |
| 38066554 | Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms. | Exp Hematol Oncol | 2023 | https://conductscience.org/library/papers/38066554 | PubMed |
| 37831007 | A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. | Clin Cancer Res | 2024 | https://conductscience.org/library/papers/37831007 | PubMed |
| 37509345 | Ability of 18F-FDG Positron Emission Tomography Radiomics and Machine Learning in Predicting KRAS Mutation Status in Therapy-Naive Lung Adenocarcinoma. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37509345 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| GAPDH | 2597 | PubTator's text mining | https://conductscience.org/library/genes/2597 | NCBI Gene |
| HRAS | 3265 | PubTator's text mining | https://conductscience.org/library/genes/3265 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| MAP2K7 | 5609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| NRAS | 4893 | PubTator's text mining | https://conductscience.org/library/genes/4893 | NCBI Gene |
| ZHX2 | 22882 | PubTator's text mining | https://conductscience.org/library/genes/22882 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37339170
GET https://conductscience.org/api/papers/v1/37339170/authors